
Bristol Drug Eases Alzheimer Psychosis
Preliminary late-stage data shows Bristol Myers Squibb drug Cobenfy improved psychosis symptoms in Alzheimer patients. The treatment reduced hallucinations and delusions while maintaining low discontinuation rates.
Xurve View
Insights:
Xurve View

Bristol-Myers Squibb Co reported positive preliminary data from two late-stage studies showing Cobenfy improved psychosis symptoms in Alzheimer's patients during a Wednesday morning update. Investors are closely tracking label expansion prospects for the drug, which is already approved in the United States for schizophrenia treatment. The new results mark a critical milestone for the drugmaker's neurological portfolio and long-term growth strategy.











